The 2,000 heart donors available annually continue to be inadequate for the 50,000 patients with end-stage congestive heart failure who require heart transplantation to survive. This discrepancy has led to the successful use of long-term implantable LVADs as a bridge to transplantation and has raised the issue of permanent device implantation in lieu of transplantation. The recent support by Food and Drug Administration medical advisory panel for widespread release of an implantable, long-term LVAD as a bridge to transplantation makes more widespread of the devices likely and mandates improved clinician awareness of the benefits and limitations of this new technology. We outline our indications and contraindications for insertion of implantable LVADs based on our 4-year clinical experience with 29 patients.